ADC Therapeutics — Third Quarter 2026 Earnings Summary

ADC Therapeutics reported third-quarter 2026 net product revenue of $21 million and a net loss of $25.3 million, while maintaining $189.2 million in cash and cash equivalents as of September 30, 2026. The company strengthened its balance sheet through a strategic financial restructuring in October 2026, which included an $86.6 million PIPE financing and amendments to existing debt agreements, extending its cash runway into 2029. Multiple clinical abstracts for ZYNLONTA, including full results from the LOTIS-5 trial and data from the LOTIS-7 combination study, were accepted for presentation at the ASH 2026 meeting. Additionally, the company's Japanese partner Tanabe Pharma submitted a marketing authorization application for ZYNLONTA in Japan and established an exclusive sublicensing agreement with Nippon Shinyaku for commercialization.